Please login to the form below

Not currently logged in
Email:
Password:

Cardinal health profits rise on sale of technology and services arms

US-headquartered medical products manufacturer Cardinal Health has said that its Q4 profits were augmented by gains made from the USD 3.3bn sale of its pharmaceutical technologies and services segment.

US-headquartered medical products manufacturer Cardinal Health has said that its Q4 profits were augmented by gains made from the USD 3.3bn sale of its pharmaceutical technologies and services segment.

The company racked up net profits of USD 902.2m, or USD 2.33 per share, compared with USD 321.1m, or USD 0.76 per share for the previous year's quarter. Revenue rose to USD 22.3bn from USD 21.3bn, while earnings from discontinued operations reached USD 664.5m.

Cardinal revealed that it earned USD 0.63 per share. Excluding one-time items and charges from continuing operations, the company made a profit of USD 0.89 per share. In a Thomson Financial poll of analysts, the expected gains were USD 0.87 per share on revenue of USD 22.6bn.

The drop in profit from continuing operations was attributed to the USD 1.4bn purchase of US medical devices firm, Viasys.

Cardinal's healthcare supply chain services and pharmaceutical business grew four per cent to rest at USD 19.6bn, while sales for that segment increased five per cent to rest at USD 1.9bn.

For the full year, Cardinal earned USD 1.9bn, or USD 4.77 per share, compared with a profit of USD 1bn, or USD 2.33 per share for the previous year. Excluding discontinued operations, the company earned USD 2.07 per share.

10th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics